锦欣生殖医疗集团有限公司是一家投资控股公司，主要提供试管受精（IVF）服务。该公司通过其子公 司主要提供辅助生殖服务、管理服务、流动手术中心设施服务、辅助医疗服务、妇产儿科医疗服务，以 及从事医疗消耗品及设备销售业务。该公司主要在中国及美国提供服务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-12-01 | 14.85 Z | 290.25万 | 0.20% | | 2025-11-28 | 14.82亿 | 435.70万 | 0.29% | | 2025-11-27 | 14.78亿 | 348.85万 | 0.24% | | 2025-11-26 | 14.74亿 | 629.85万 | 0.43% | | 2025-11-25 | 14.68亿 | 1007.25万 | 0.69% | 证券之星消息，12月1日南向资金增持290.25万股锦欣生殖（01951.HK）。近5个交易日中，获 ...

Group 1 - Southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 6.2985 million shares on November 26, 2025, marking a 0.43% change [1][2] - Over the past five trading days, there have been five days of net increases in holdings, totaling 20.795 million shares [1][2] - In the last 20 trading days, there were 13 days of net increases, amounting to 31.1263 million shares [1][2] Group 2 - As of now, southbound funds hold 1.474 billion shares of Jinxin Reproductive Medicine, representing 53.44% of the company's total issued ordinary shares [1][2] - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and sales of medical consumables and equipment, mainly in China and the United States [2]

Core Insights - Southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 611,000 shares on November 24, 2025, marking a consistent trend of net increases over recent trading days [1] - Over the past 5 trading days, there has been a cumulative net increase of 11.76 million shares, while in the last 20 trading days, the total net increase reached 12.71 million shares [1] - As of now, southbound funds hold 1.458 billion shares of Jinxin Reproductive Medicine, accounting for 52.84% of the company's total issued ordinary shares [1] Summary by Category Trading Activity - On November 24, 2025, total shares held reached 1.458 billion, with a change of 611,000 shares, reflecting a 0.04% increase [2] - On November 21, 2025, total shares held were 1.457 billion, with a change of 630,000 shares, also a 0.04% increase [2] - On November 20, 2025, total shares held were 1.456 billion, with a change of 3.183 million shares, indicating a 0.22% increase [2] - On November 19, 2025, total shares held were 1.453 billion, with a change of 3.168 million shares, also a 0.22% increase [2] - On November 18, 2025, total shares held were 1.450 billion, with a change of 4.170 million shares, reflecting a 0.29% increase [2] Company Overview - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and maternal and pediatric medical services [2] - Jinxin Reproductive Medicine operates mainly in China and the United States [2]

Core Insights - Southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 3.168 million shares on November 19, 2025, marking a 0.22% increase in total shares held [1][2] - Over the past five trading days, there have been four days of net increases in holdings, totaling 6.8563 million shares [1] - In the last twenty trading days, there were ten days of net increases, amounting to 9.4968 million shares [1] - As of now, southbound funds hold 1.453 billion shares of Jinxin Reproductive Medicine, representing 52.69% of the company's total issued ordinary shares [1] Company Overview - Jinxin Reproductive Medicine Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and maternal and pediatric medical services [2] - Jinxin operates mainly in China and the United States, also engaging in the sale of medical consumables and equipment [2]

Core Insights - Southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 4.17 million shares on November 18, 2025, bringing the total holdings to 1.45 billion shares, which represents 52.58% of the company's issued ordinary shares [1][2] Group 1: Shareholding Changes - Over the past five trading days, there were two days of net reductions in holdings by southbound funds, totaling a net decrease of 686,700 shares [1] - In the last 20 trading days, there were ten days of net increases in holdings by southbound funds, with a cumulative net increase of 8.73 million shares [1] Group 2: Company Overview - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and sales of medical consumables and equipment [2] - The company's services are mainly provided in China and the United States [2]

Group 1 - The core point of the news is that southbound funds have increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 1.466 million shares on November 13, 2025, with a total net increase of 4.3525 million shares over the last five trading days [1] - Over the past 20 trading days, there have been 11 days of net increases in holdings by southbound funds, totaling 13.1125 million shares [1] - As of now, southbound funds hold 1.448 billion shares of Jinxin Reproductive Medicine, accounting for 52.5% of the company's issued ordinary shares [1] Group 2 - The company, Jinxin Reproductive Medicine, is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and sales of medical consumables and equipment [2] - Jinxin Reproductive Medicine operates mainly in China and the United States [2]

Group 1 - The core point of the article highlights the recent trading activity of southbound funds in Jinxin Reproductive Medicine (01951.HK), indicating a reduction in holdings on November 12, 2025, by 4.375 million shares [1] - Over the past five trading days, there were two days of net increases in holdings by southbound funds, totaling a net increase of 4.909 million shares [1] - In the last twenty trading days, there were eleven days of net increases, with a cumulative net increase of 22.877 million shares [1] Group 2 - As of November 12, 2025, southbound funds hold a total of 1.446 billion shares of Jinxin Reproductive Medicine, representing 52.44% of the company's issued ordinary shares [1] - The trading data shows fluctuations in shareholdings, with a decrease of 0.30% on November 12, 2025, and a previous decrease of 0.07% on November 11, 2025 [2] - The company primarily provides in vitro fertilization (IVF) services and operates in China and the United States, offering a range of reproductive and medical services [2]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Jinxin Reproductive Medicine (01951.HK) by 7.45 million shares on November 3, 2025, marking a decrease of 0.52% [1][2] - Over the past five trading days, there have been four days of net reductions in holdings, totaling 8.89 million shares [1][2] - In the last 20 trading days, there were 11 days of net increases in holdings, amounting to a total of 15.63 million shares [1][2] Group 2 - As of now, southbound funds hold 1.436 billion shares of Jinxin Reproductive Medicine, which represents 52.07% of the company's total issued ordinary shares [1][2] - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services, along with various reproductive and medical services [2] - The company operates mainly in China and the United States, offering auxiliary reproductive services, management services, and sales of medical consumables and equipment [2]

Group 1 - The core point of the news is that southbound funds have reduced their holdings in Jinxin Fertility (01951.HK) by 1.742 million shares on October 27, 2025, while there have been net increases in holdings on 3 out of the last 5 trading days, totaling a net increase of 1.876 million shares [1] - Over the last 20 trading days, Jinxin Fertility has seen net increases in holdings for 13 days, with a total net increase of 23.729 million shares [1] - As of now, southbound funds hold 1.443 billion shares of Jinxin Fertility, accounting for 52.33% of the company's total issued ordinary shares [1] Group 2 - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers assisted reproductive services, management services, mobile surgical center facility services, auxiliary medical services, obstetrics and pediatrics medical services, as well as sales of medical consumables and equipment [2] - Jinxin Fertility operates mainly in China and the United States [2]

Core Viewpoint - Southbound funds have significantly increased their holdings in Jinxin Reproductive Medicine (01951.HK), indicating strong investor interest and confidence in the company’s performance and growth potential [1][2]. Group 1: Shareholding Changes - On October 24, southbound funds increased their holdings by 3.651 million shares, representing a 0.25% change [2]. - Over the past five trading days, there were four days of net increases, totaling 3.666 million shares [1]. - In the last 20 trading days, there were 14 days of net increases, amounting to 36.725 million shares [1]. Group 2: Current Shareholding Status - As of October 24, southbound funds hold a total of 1.445 billion shares of Jinxin Reproductive Medicine, which constitutes 52.39% of the company's total issued ordinary shares [1][2]. Group 3: Company Overview - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2]. - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and sales of medical consumables and equipment [2]. - The company operates mainly in China and the United States [2].